Satellos Bioscience presents early adult data for Duchenne muscular dystrophy pill ahead of child trial

Satellos Bioscience, a Canadian biotech, has released early results from its Phase 2 study of an oral therapy for Duchenne muscular dystrophy in adult patients. The data are intended to strengthen the company’s case as it prepares for a potentially pivotal trial in children later this year.

The adult study marks the first time the investigational pill has been evaluated in humans, providing initial safety and pharmacology information. While detailed efficacy outcomes were not disclosed, the company highlighted that the findings support continued development.

Satellos plans to initiate the pediatric trial, which could serve as a pivotal readout for regulatory approval if the results are favorable. The upcoming child study is expected to be a key milestone for the company and its investors.

Analysts will watch the pediatric data closely, as a successful outcome could position Satellos as a notable player in the Duchenne therapeutic landscape.